Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study

Journal of the American College of Cardiology

Volumn 35, Issue 1, 2000, Pages 89-95

  Marian, Ali J ^a   Safavi, Faye ^a   Ferlic, Laura ^a   Dunn, J Kay ^a   Gotto, Antonio M ^b   Ballantyne, Christie M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; FEMALE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL;

ADULT; AGED; CHOLESTEROL, LDL; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 0033957209     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00535-5     Document Type: Article

References (33)

1. Hennekens C.H. Increasing burden of cardiovascular disease current knowledge and future directions for research on risk factors . Circulation. 97:1998;1095-1102.
2. Slack J., Evans K.A. The increased risk of death from ischemic heart disease in first degree relatives of 121 men and 96 women with ischemic heart disease. J Med Genetics. 3:1966;239-257.
3. Marenberg M.E., Risch N., Berkman L.F., Floderus B., de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 330:1994;1041-1046.
4. Marian A.J. Genetic risk factors for myocardial infarction. Curr Opin Cardiol. 13:1998;171-178.
5. Dullaart R.P., Hoogenberg K., Riemens S.C., et al. Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid-lowering diet in type 1 diabetes. Diabetes. 46:1997;2082-2087.
6. Ordovas J.M., Lopez-Miranda J., Mata P., Perez-Jimenez F., Lichtenstein A.H., Schaefer E.J. Gene-diet interaction in determining plasma lipid response to dietary intervention. Atherosclerosis. 118:(Suppl):1995;S11-S27.
7. Brenn T. Genetic and environmental effects on coronary heart disease risk factors in northern Norway. The cardiovascular disease study in Finnmark. Ann Hum Genet. 58:1994;369-379.
8. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science. 265:1994;2037-2048.
9. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 86:1990;1343-1346.
10. Danser A.H., Schalekamp M.A., Bax W.A., et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation. 92:1995;1387-1388.
11. Costerousse O., Allegrini J., Lopez M., Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells genetic polymorphism of expression in T-lymphocytes . Biochem J. 290:1993;33-40.
12. Dzau V.J. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J. 19:(Suppl J):1998;J2-J6.
13. Herd JA, Ballantyne CM, Farmer JA, et al, for LCAS investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoportein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.
14. West MS, Herd JA, Ballantyne CM, et al, for LCAS investigators. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials 1996;17:550-83.
15. Ballantyne C.M., Herd J.A., Ferlic L.L., et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 99:1999;736-743.
16. Dakik H.A., Mahmarian J.J., Verani M.S., Farmer J.A., Zhao G., Marian A.J. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol. 29:1997;1468-1473.
17. Shanmugam V., Sell K.W., Saha B.K. Mistyping ACE heterozygotes. PCR Methods Appl. 3:1993;120-121.
18. Lindpaintner K., Pfeffer M.A., Kreutz R., et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 332:1995;706-711.
19. Lander E., Kruglyak L. Genetic dissection of complex traits guidelines for interpreting and reporting linkage results . Nat Genet. 11:1995;241-247.
20. Tukey J.W. The philosophy of multiple comparisons. Statistical Science. 6:1991;100-116.
21. van Geel P.P., Pinto Y.M., Zwinderman A.H., et al. The angiotensin-converting enzyme deletion-type gene is associated with ischemic events and a blunted effect on lipid-lowering treatment on angiographically defined coronary atherosclerosis. Eur Heart J. 18:(Suppl):1997;486.
22. Aviram M., Hussein O., Rosenblat M., Schlezinger S., Hayek T., Keidar S. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia antiatherogenic effects of HMG-CoA reductase inhibitor therapy . J Cardiovasc Pharmacol. 31:1998;39-45.
23. Mombouli J.V. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs. 54:(Suppl 5):1997;12-22.
24. Scheidegger K.J., Butler S., Witztum J.L. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem. 272:1997;21609-21615.
25. Keidar S., Kaplan M., Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol. 16:1996;97-105.
26. Leitersdorf E., Stein O., Stein Y. Angiotensin II stimulates receptor-mediated uptake of LDL by bovine adrenal cortical cells in primary culture. Biochim Biophys Acta. 835:1985;183-190.
27. Hussein O., Schlezinger S., Rosenblat M., et al. Reduced susceptibility of low density lipoprotein to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis. 128:1997;11-18.
28. Cholerton S., Daly A.K., Idle J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 13:1992;434-439.
29. Aalto-Setala K., Kontula K., Manttari M., et al. DNA polymorphisms of apolipoprotein B and AI/CIII genes and response to gemfibrozil treatment. Clin Pharmacol Ther. 50:1991;208-214.
30. Nestruck A.C., Bouthillier D., Sing C.F., Davignon J. Apolipoprotein E polymorphism and plasma cholesterol response to probucol. Metabolism. 36:1987;743-747.
31. McCombs R.J., Marcadis D.E., Ellis J., Weinberg R.B. Attenuated hypercholesterolemic response to a high-cholesterol diet in subjects heterozygous for the apolipoprotein A-IV-2 allele. N Engl J Med. 331:1994;706-710.
32. Arranz M., Collier D., Sodhi M., et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet. 346:1995;281-282.
33. Cusi D., Barlassina C., Azzani T., et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet. 349:1997;1353-1357.